Recent Updates
Recently added Catalysts
HIMS Positive Sentiment

Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership

Thursday, October 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Hims & Hers Health, Inc. has appointed Kultar Garcha as Chief Medical Officer for the UK and EMEA, and Matt Vickers as Chief Medical Officer for Australia. These appointments aim to enhance local clinical leadership and improve health services in these regions. The move reflects the company's commitment to investing in global health and wellness.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of experienced medical leaders in key regions.
  • Strengthening local clinical leadership for better service.
  • Expansion of the global medical leadership team.

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced two new clinical experts will join its global medical leadership team, led by Global Chief Medical Officer Pat Carroll, MD. Kultar Garcha, MD, will serve as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, will serve as Chief Medical Officer of Hims Australia. The appointments mark the company’s latest step in streng

Frequently Asked Questions

Who are the new Chief Medical Officers at Hims & Hers?

Kultar Garcha will serve as CMO for the UK and EMEA, while Matt Vickers will be CMO for Australia.

What is the goal of these new appointments?

The appointments aim to strengthen local clinical leadership and improve health services.

Who leads the global medical leadership team at Hims & Hers?

The global medical leadership team is led by Pat Carroll, MD.

What regions will the new CMOs oversee?

Kultar Garcha will oversee the UK and EMEA, and Matt Vickers will oversee Australia.

ShareAdd on Google
Tags: HIMS Hims & Hers Kultar Garcha Matt Vickers clinical leadership health services
Last updated: Oct 1, 2026

Biotech snapshot

Cash runway
$841M liquidity · $12M/mo burn
~69 mo
Minimal dilution risk